News & Updates
Filter by Specialty:
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
Treatment with cefoperazone-sulbactam demonstrates similar efficacy to that of piperacillin-tazobactam in adult patients with severe community-acquired pneumonia (SCAP), according to a study. However, after adjusting for disease severity, cefoperazone-sulbactam appears superior to piperacillin-tazobactam.
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
21 Sep 2023
Zuranolone improves symptoms in adults with major depressive disorder
Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.
Zuranolone improves symptoms in adults with major depressive disorder
21 Sep 2023
Budesonide falls short of improving hyposmia related to COVID-19
Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.
Budesonide falls short of improving hyposmia related to COVID-19
21 Sep 2023
Zuranolone safe, effective for postpartum depression
Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.
Zuranolone safe, effective for postpartum depression
20 Sep 2023
NSAIDs up VTE risk in women using hormonal contraception
Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.
NSAIDs up VTE risk in women using hormonal contraception
20 Sep 2023
Colorectal cancer screening can wait until age 50
Colorectal cancer screening should wait until age 50 for average-risk, asymptomatic adults, says the American College of Physicians (ACP) in its updated guidance. However, this stands in contrast to screening recommendations by the American Cancer Society (ACS) and the US Preventive Services Task Force (USPSTF) to start at age 45.